Abstract:Chao Hong, 1, 2, &ast Anni Wang, 1, &ast Jiaxuan Xia, 1 Jianming Liang, 1, 3 Ying Zhu, 1 Dan Wang, 1, 4 Huaxing Zhan, 4 Chunbo Feng, 5 Xinnan Jiang, 5 Junjie Pan, 6 Jianxin Wang 1, 7 1 Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People's Republic of China; 2 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China; 3 Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, People's Republic of China; 4 Xiamen Ginposome Pharmaceutical Co., Ltd, Xiamen, 361026, People's Republic of China; 5 R&D Center, Shanghai Jahwa United Co., Ltd, Shanghai, 200082, People's Republic of China; 6 Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China; 7 Institute of Integrated Chinese and Western Medicine, Fudan University, Shanghai, 200040, People's Republic of China &astThese authors contributed equally to this work Correspondence: Junjie Pan; Jianxin Wang, Email ; Background: Most solid tumors are not diagnosed and treated until the advanced stage, in which tumors have shaped mature self-protective power, leading to off-target drugs and nanomedicines. In the present studies, we established a more realistic large tumor model to test the antitumor activity of a multifunctional ginsenoside Rh2-based liposome system (Rh2-lipo) on advanced breast cancer. Methods: Both cholesterol and PEG were substituted by Rh2 to prepare the Rh2-lipo using ethanol-water system and characterized. The effects of Rh2-lipo on cell uptake, penetration of the tumor spheroid, cytotoxicity assay was investigated with 4T1 breast cancer cells and L929 fibroblast cells. The 4T1 orthotopic-bearing large tumor model was established to study the targeting effect of Rh2-lipo and inhibitory effect of paclitaxel loaded Rh2-lipo (PTX-Rh2-lipo) on advanced breast tumors. Results: Rh2-lipo exhibit many advantages that address the limitations of current liposome formulations against large tumors, such as enhanced uptake in TAFs and tumor cells, high targeting and penetration capacity, cytotoxicity against TAFs, normalization of the vessel network, and depletion of stromal collagen. In in vivo study, PTX-Rh2-lipo effectively inhibiting the growth of advanced breast tumors and outperformed most reported PTX formulations, including Lipusu ® and Abraxane ® . Conclusion: Rh2-lipo have improved drug delivery efficiency and antitumor efficacy in advanced breast cancer, which offers a novel promising platform for advanced tumor therapy. Keywords: nanomedicine, tumor microenvironment, chemotherapy, tumor-associated fibroblast Graphical Cancer remains a highly fatal disease in the world. The past three decades have witnessed a great expansion of research in the field of cancer nanomedicine. Various nanoparticles that include lipid-based nanoparticles, polymeric nanoparticles, and inorganic nanoparticles have been developed for targeted delivery of therapeutic nucleic acids, 1 chemotherapeutic agents, 2 or immunotherapeutic agents to tumors. 3 The advantage of using nanomedicines to treat cancer is that they can effectively target and deliver drugs to the tumor site, 4 reducing side effects and improving treatment efficiency. In addition, nanomedicines have a controlled release function, allowing drugs to be slowly released at the tumor site, reducing the frequency of dosing, and improving patient compliance. 5 However, there is a large body of literature describing different nanoparticles as potential cancer therapies, yet only a handful has been US Food and Drug Administration (FDA) approved. 6 The tumor microenvironment (TME) is well known for its important role in cancer development and metastasis 7–9 Various cells in the TME, especially stromal cells, including tumor-associated fibroblasts (TAFs), collagen, and endothelial cells, form a physical barrier within tumors to inhibit penetration of therapeutic nanoparticles and secrete growth-inducing cytokines and growth factors to facilitate the survival of tumor cells, which finally results in the resistance of nanochemotherapy 7,9 Evidence has shown that in the early stages of tumor growth, the composite of the TME is much simpler and far from shaping self-protective mechanisms. 10 When tumor grow -Abstract Truncated-

Versatile ginsenoside Rg3 liposomes inhibit tumor metastasis by capturing circulating tumor cells and destroying metastatic niches

Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells

Targeting Therapy and Tumor Microenvironment Remodeling of Triple-Negative Breast Cancer by Ginsenoside Rg3 Based Liposomes

Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells

Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviating toxicity

Multifunctional Ginsenoside Rg3-based Liposomes for Glioma Targeting Therapy.

Multifunctional Biomimetic Liposomes with Improved Tumor‐Targeting for TNBC Treatment by Combination of Chemotherapy, Anti‐Angiogenesis and Immunotherapy

Micellar Nanoparticles Inhibit Breast Cancer and Pulmonary Metastasis by Modulating the Recruitment and Depletion of Myeloid-Derived Suppressor Cells.

Development of Liposomal Ginsenoside Rg3: Formulation Optimization and Evaluation of Its Anticancer Effects

One Stone Four Birds: A Novel Liposomal Delivery System Multi-functionalized with Ginsenoside Rh2 for Tumor Targeting Therapy

Tumor-Targeting Micelles Based on Linear Dendritic PEG-PTX8 Conjugate for Triple Negative Breast Cancer Therapy

EGFR-Targeted Liposomes Combined with Ginsenoside Rh2 Inhibit Triple-Negative Breast Cancer Growth and Metastasis

Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis

Increased Tumor Targeted Delivery Using a Multistage Liposome System Functionalized with RGD, TAT and Cleavable PEG.

Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy

Platelet-camouflaged Nanococktail: Simultaneous Inhibition of Drug-Resistant Tumor Growth and Metastasis Via a Cancer Cells and Tumor Vasculature Dual-Targeting Strategy

Effective treatment of the primary tumor and lymph node metastasis by polymeric micelles with variable particle sizes

Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles

Integrin αvβ3-targeted liposomal drug delivery system for enhanced lung cancer therapy

Bioinspired Ginsenoside Rg3 PLGA Nanoparticles Coated with Tumor-Derived Microvesicles to Improve Chemotherapy Efficacy and Alleviate Toxicity

Enhanced Anticancer Efficacy of Paclitaxel Through Multistage Tumor-Targeting Liposomes Modified with RGD and KLA Peptides